Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference

Gain Therapeutics (NASDAQ: GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside chat at a Roth Capital Partners conference. The discussion, hosted by Roth managing director and senior biotech analyst Boobalan Pachaiyappan, centered on Parkinson's unmet need, the company's drug-discovery